S.B. No. 670 is a legislative act aimed at enhancing patient access to investigational sun protection products that have completed phase one of clinical trials but are not yet approved by the U.S. Food and Drug Administration (FDA). The bill establishes a new chapter in the Health and Safety Code, specifically Chapter 491, which outlines the definitions, eligibility criteria, informed consent requirements, and provisions for accessing these investigational products. It emphasizes that patients, in consultation with their physicians, should have the right to make decisions regarding their health and access to potentially life-saving products without government interference.

Key provisions of the bill include the requirement for physicians to determine that approved sun protection products are less effective before recommending an investigational product, and the necessity for patients to provide informed consent. Additionally, the bill protects manufacturers from liability for harm resulting from the use of these products and prohibits state officials from obstructing patient access. The Texas Medical Board is also restricted from taking action against physicians solely based on their recommendations for these investigational products, provided they adhere to medical standards and the requirements set forth in the new chapter.

Statutes affected:
Introduced: ()
Senate Committee Report: ()
Engrossed: ()
House Committee Report: ()
Enrolled: ()